A. Mackie

Most-cited papers

1. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects.

   A. Mackie, G. Ventresca, R. Fuller, A. Bye

   2003British Journal of Clinical Pharmacology76 citations Open access

   Semantic Scholar

   Save

2. Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate

   S. Rohatagi, A. Bye, C. Falcoz, A. Mackie +3 more

   1996Journal of clinical pharmacology54 citations

   Semantic Scholar

   Save

3. Mathematical modeling of cortisol circadian rhythm and cortisol suppression

   S. Rohatagi, A. Bye, A. Mackie, H. Derendorf

   199653 citations

   Semantic Scholar

   Save

4. Pharmacokinetics of Fluticasone Propionate Inhaled via the Diskhaler® and Diskus® Powder Devices in Healthy Volunteers

   A. Mackie, J. E. McDowall, C. Falcoz, P. Ventresca +2 more

   2000Clinical Pharmacokinetics45 citations

   Semantic Scholar

   Save

5. Systemic Exposure to Fluticasone Propionate Administered via Metered-Dose Inhaler Containing Chlorofluorocarbon or Hydrofluoroalkane Propellant

   A. Mackie, J. E. McDowall, P. Ventresca, A. Bye +2 more

   2000Clinical Pharmacokinetics35 citations

   Semantic Scholar

   Save

6. Absorption Kinetics after Inhalation of Fluticasone Propionate via the Diskhaler®, Diskus® and Metered-Dose Inhaler in Healthy Volunteers

   C. Brindley, C. Falcoz, A. Mackie, A. Bye

   2000Clinical Pharmacokinetics28 citations

   Semantic Scholar

   Save

7. Pharmacokinetics and Bioavailability of Intranasal Fluticasone in Humans

   J. E. McDowall, A. Mackie, G. Ventresca, A. Bye

   199726 citations

   Semantic Scholar

   Save

8. The Relationship between Systemic Exposure to Fluticasone Propionate and Cortisol Reduction in Healthy Male Volunteers

   A. Mackie, A. Bye

   2000Clinical Pharmacokinetics20 citations

   Semantic Scholar

   Save

9. Pharmacokinetics of Fluticasone Propionate Inhaled via the Diskhaler® and Diskus® Powder Devices in Patients with Mild-to-Moderate Asthma

   C. Falcoz, J. Horton, A. Mackie, S. M. Harding +1 more

   2000Clinical Pharmacokinetics20 citations

   Semantic Scholar

   Save

10. Population Dose-Response Model for Tadalafil in the Treatment of Male Erectile Dysfunction

    A. Staab, C. Tillmann, S. Forgue, A. Mackie +3 more

    2004Pharmaceutical Research18 citations

    Semantic Scholar

    Save

11. Pergolide: Multiple-Dose Pharmacokinetics in Patients with Mild to Moderate Parkinson Disease

    C. Thalamas, I. Rajman, J. Kulisevsky, A. Lledo +5 more

    2005Clinical neuropharmacology15 citations

    Semantic Scholar

    Save

12. Very low systemic exposure to intranasal fluticasone propionate

    J. E. McDowall, A. Mackie, A. Bye, G. Ventresca

    199515 citations

    Semantic Scholar

    Save

13. First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers

    A. Mackie, J. Rascher, M. Schmid, V. Endriss +2 more

    2020ERJ Open Research9 citations Open access

    Semantic Scholar

    Save

14. Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects.

    D. Baldoni, A. Mackie, M. Gutierrez, R. Theodor +1 more

    2013Clinical Therapeutics7 citations

    Semantic Scholar

    Save

15. Beta-adrenoceptor subtypes mediating the airways response to BRL 35135 in man.

    D. Newnham, C. Ingram, A. Mackie, B. Lipworth

    1993British Journal of Clinical Pharmacology5 citations Open access

    Semantic Scholar

    Save

16. Modeling the Two -Peak Phenomenon in Pharmacokinetics Using a Gut Passage Model with two Absorption Sites

    Andreas Krause, M. Lavielle, K. Chatel, C. Kohl +5 more

    20132 citations

    Semantic Scholar

    Save

17. LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist

    E. Bateman, A. Mackie, Ewald Benediktus, C. Schepers +5 more

    20160 citations

    Semantic Scholar

    Save